Astaxanthin as a potential therapeutic agent in polycystic ovary syndrome: a review of its antioxidant, anti-inflammatory, and metabolic mechanisms
Abstract
Polycystic ovary syndrome (PCOS) is the most common heterogeneous disorder among women of reproductive age, characterized by hyperandrogenism, ovulatory dysfunction, and polycystic ovarian morphological changes as its core clinical features. This disease severely affects women's reproductive health and significantly increases the risk of metabolic complications. The pathogenesis of PCOS is complex, involving various pathophysiological mechanisms such as oxidative stress, chronic low-grade inflammation, and insulin resistance. Currently, lifestyle interventions and first-line pharmacological treatments are the primary clinical strategies for managing PCOS. However, existing approaches face numerous limitations in terms of efficacy, safety, and patient compliance, including incomplete therapeutic effects, drug-related side effects, poor adherence, and a lack of long-term safety data, which necessitate further optimization and breakthroughs. Natural compounds have been widely utilized as therapeutic agents worldwide, with some showing potential advantages in preclinical and pharmacological studies, positioning them as potential alternatives to modern drugs. In recent years, astaxanthin, a natural compound, has garnered attention for its auxiliary effects in the treatment of PCOS due to its potent antioxidant and anti-inflammatory properties. Astaxanthin, a strong natural antioxidant derived from Haematococcus pluvialis, exhibits significant antioxidant, anti-inflammatory,…
Read the paper
Related studies
- Increased expression of circulating miRNA-93 in women with polycystic ovary syndrome may represent a novel, non-invasive biomarker for diagnosis
- Identification of key genes associated with polycystic ovary syndrome (PCOS) and ovarian cancer using an integrated bioinformatics analysis
- Identification of key pathways and genes in polycystic ovary syndrome via integrated bioinformatics analysis and prediction of small therapeutic molecules
- Regulation of Androgen Receptor Expression Alters AMPK Phosphorylation in the Endometrium: In Vivo and In Vitro Studies in Women with Polycystic Ovary Syndrome
- Effect of oral administration of low-dose follicle stimulating hormone on hyperandrogenized mice as a model of polycystic ovary syndrome
- Systems pharmacology to investigate the interaction of berberine and other drugs in treating polycystic ovary syndrome
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.